Rodney Young
Director of Finance/CFO at RAPT THERAPEUTICS, INC.
Net worth: 105 353 $ as of 2024-03-30
Rodney Young active positions
Companies | Position | Start | End |
---|---|---|---|
RAPT THERAPEUTICS, INC. | Director of Finance/CFO | 2019-12-01 | - |
Corporate Secretary | 2019-12-01 | - |
Career history of Rodney Young
Former positions of Rodney Young
Companies | Position | Start | End |
---|---|---|---|
Cellerant Therapeutics, Inc.
Cellerant Therapeutics, Inc. Medical SpecialtiesHealth Technology Cellerant Therapeutics, Inc. develops stem cell-based cellular and antibody therapeutics for blood disorders and cancer. The firm focuses on curative therapies for seriously ill patients and is developing a cell-based medicine as a treatment for chemotherapy and radiation-induced neutropenia as well as for Acute Radiation Syndrome. The company was founded by Irving L. Weissman in 2003 and is headquartered in San Carlos, CA. | Director of Finance/CFO | 2015-06-15 | 2019-10-31 |
AIMMUNE THERAPEUTICS, INC. | Director of Finance/CFO | 2014-04-30 | 2015-01-31 |
StemCells, Inc.
StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | Director of Finance/CFO | 2005-08-31 | 2013-11-30 |
Investor Relations Contact | 2005-08-31 | 2013-11-30 | |
Public Communications Contact | - | 2013-11-30 | |
Extropy Pharmaceuticals, Inc. | Director of Finance/CFO | 2002-12-31 | 2004-12-31 |
Training of Rodney Young
The University of Chicago | Undergraduate Degree |
The University of Chicago Booth School of Business | Masters Business Admin |
Statistics
International
United States | 8 |
Operational
Director of Finance/CFO | 5 |
Undergraduate Degree | 1 |
Investor Relations Contact | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
RAPT THERAPEUTICS, INC. | Health Technology |
Private companies | 4 |
---|---|
StemCells, Inc.
StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | Health Technology |
Cellerant Therapeutics, Inc.
Cellerant Therapeutics, Inc. Medical SpecialtiesHealth Technology Cellerant Therapeutics, Inc. develops stem cell-based cellular and antibody therapeutics for blood disorders and cancer. The firm focuses on curative therapies for seriously ill patients and is developing a cell-based medicine as a treatment for chemotherapy and radiation-induced neutropenia as well as for Acute Radiation Syndrome. The company was founded by Irving L. Weissman in 2003 and is headquartered in San Carlos, CA. | Health Technology |
Extropy Pharmaceuticals, Inc. | |
Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
- Stock Market
- Insiders
- Rodney Young
- Experience